Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California. more
Time Frame | UNCY | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.29% | -0.94% | -2.6% |
1-Month Return | 19.98% | -5.08% | -1.08% |
3-Month Return | 55.85% | -10.62% | 3.45% |
6-Month Return | -2.89% | -6.18% | 8.57% |
1-Year Return | 10.5% | 1.98% | 24.3% |
3-Year Return | -68.28% | -0.93% | 25.58% |
5-Year Return | -86.74% | 33.84% | 84.07% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 951.00K | 675.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.98,"profit":true}] |
Cost of Revenue | - | - | 1.00K | 7.00K | 284.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":0.35,"profit":true},{"date":"2022-12-31","value":2.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | - | - | (1.00K) | 951.00K | 675.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-0.11,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.98,"profit":true}] |
Gross Margin | - | - | - | 100.00% | 100.00% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 1.96M | 2.02M | 8.98M | 19.00M | 21.45M | [{"date":"2019-12-31","value":9.15,"profit":true},{"date":"2020-12-31","value":9.42,"profit":true},{"date":"2021-12-31","value":41.85,"profit":true},{"date":"2022-12-31","value":88.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (1.96M) | (2.02M) | (8.98M) | (18.05M) | (20.77M) | [{"date":"2019-12-31","value":-196300000,"profit":false},{"date":"2020-12-31","value":-202000000,"profit":false},{"date":"2021-12-31","value":-897700000,"profit":false},{"date":"2022-12-31","value":-1805200000,"profit":false},{"date":"2023-12-31","value":-2077400000,"profit":false}] |
Total Non-Operating Income/Expense | (341.00K) | (488.00K) | (1.67M) | (12.00K) | (9.36M) | [{"date":"2019-12-31","value":-34100000,"profit":false},{"date":"2020-12-31","value":-48800000,"profit":false},{"date":"2021-12-31","value":-166800000,"profit":false},{"date":"2022-12-31","value":-1200000,"profit":false},{"date":"2023-12-31","value":-936100000,"profit":false}] |
Pre-Tax Income | (2.17M) | (2.26M) | (10.02M) | (18.06M) | (30.54M) | [{"date":"2019-12-31","value":-216500000,"profit":false},{"date":"2020-12-31","value":-226400000,"profit":false},{"date":"2021-12-31","value":-1001700000,"profit":false},{"date":"2022-12-31","value":-1805800000,"profit":false},{"date":"2023-12-31","value":-3054400000,"profit":false}] |
Income Taxes | 139.00K | 244.00K | 615.00K | 6.00K | 116.11K | [{"date":"2019-12-31","value":22.6,"profit":true},{"date":"2020-12-31","value":39.67,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.98,"profit":true},{"date":"2023-12-31","value":18.88,"profit":true}] |
Income After Taxes | (2.30M) | (2.51M) | (10.63M) | (18.06M) | (30.66M) | [{"date":"2019-12-31","value":-230400000,"profit":false},{"date":"2020-12-31","value":-250800000,"profit":false},{"date":"2021-12-31","value":-1063200000,"profit":false},{"date":"2022-12-31","value":-1806400000,"profit":false},{"date":"2023-12-31","value":-3066010500,"profit":false}] |
Income From Continuous Operations | (2.17M) | (2.26M) | (10.02M) | (18.06M) | (28.07M) | [{"date":"2019-12-31","value":-216500000,"profit":false},{"date":"2020-12-31","value":-226400000,"profit":false},{"date":"2021-12-31","value":-1001700000,"profit":false},{"date":"2022-12-31","value":-1805800000,"profit":false},{"date":"2023-12-31","value":-2807400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (2.30M) | (2.51M) | (10.63M) | (18.06M) | (30.54M) | [{"date":"2019-12-31","value":-230400000,"profit":false},{"date":"2020-12-31","value":-250800000,"profit":false},{"date":"2021-12-31","value":-1063200000,"profit":false},{"date":"2022-12-31","value":-1806400000,"profit":false},{"date":"2023-12-31","value":-3054400000,"profit":false}] |
EPS (Diluted) | - | - | (0.57) | (1.20) | (0.92) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-57,"profit":false},{"date":"2022-12-31","value":-120,"profit":false},{"date":"2023-12-31","value":-92,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
UNCY | |
---|---|
Cash Ratio | 3.09 |
Current Ratio | 3.61 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
UNCY | |
---|---|
ROA (LTM) | -53.37% |
ROE (LTM) | -121.76% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
UNCY | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.28 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.72 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
UNCY | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 62.82 |
P/B | 2.60 |
Price/FCF | NM |
EV/R | 16.63 |
EV/Ebitda | NM |
Unicycive Therapeutics Inc (UNCY) share price today is $0.663
Yes, Indians can buy shares of Unicycive Therapeutics Inc (UNCY) on Vested. To buy Unicycive Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in UNCY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Unicycive Therapeutics Inc (UNCY) via the Vested app. You can start investing in Unicycive Therapeutics Inc (UNCY) with a minimum investment of $1.
You can invest in shares of Unicycive Therapeutics Inc (UNCY) via Vested in three simple steps:
The 52-week high price of Unicycive Therapeutics Inc (UNCY) is $1.82. The 52-week low price of Unicycive Therapeutics Inc (UNCY) is $0.2.
The price-to-earnings (P/E) ratio of Unicycive Therapeutics Inc (UNCY) is
The price-to-book (P/B) ratio of Unicycive Therapeutics Inc (UNCY) is 2.60
The dividend yield of Unicycive Therapeutics Inc (UNCY) is 0.00%
The market capitalization of Unicycive Therapeutics Inc (UNCY) is $71.00M
The stock symbol (or ticker) of Unicycive Therapeutics Inc is UNCY